Exploring Cystic Fibrosis (CF) Therapeutics Market : Projected to Surpass USD 9.27 Billion by 2026 ; Driven by Rise in the Incidence of Cystic Fibrosis Across the Globe

According to a new report published by Allied Market Research, titled, " Cystic Fibrosis Therapeutics Market by Drug Class and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2018-2026," the global cystic fibrosis therapeutics market size is expected to reach $9,277 million by 2026, registering a CAGR of 9.2% from 2019 to 2026, in terms of value.

Cystic fibrosis is a hereditary condition primarily impacting the lungs and digestive system. It results in the production of thick and sticky mucus that can obstruct the airways and hinder pancreatic function. This disease poses a significant risk to life, often resulting in a shorter-than-average lifespan. Due to its severity, all newborns in the U.S. undergo screening for cystic fibrosis.

While there is currently no cure for cystic fibrosis, managing the condition involves maintaining proper nutrition and utilizing medications to thin the excess mucus produced in the lungs and other organs, thereby improving patient longevity. Treatment options include medications like Pulmozyme and Kalydeco, which can be administered via various routes such as oral ingestion or inhalation.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 https://www.alliedmarketresearch.com/request-sample/5499

The cystic fibrosis therapeutics market is experiencing growth driven by a rise in the global incidence of cystic fibrosis and an increase in the availability of medications targeting the condition. Furthermore, investments in research and development aimed at developing drugs to treat cystic fibrosis are fueling market expansion. However, challenges such as the high cost of treatment and the introduction of generic drugs are impeding market growth.

Nonetheless, the evolving healthcare industry in developing economies presents promising opportunities for the market. Additionally, the growing prevalence of cystic fibrosis necessitates the development of newer and more advanced therapeutics, leading to an increase in pipeline drugs in the market. This trend is expected to contribute to significant market expansion during the forecast period.

In the analysis of the cystic fibrosis therapeutics market, the CFTR modulators segment emerged as the dominant category in 2018 and is expected to maintain its lead throughout the forecast period. This dominance is attributed to the increased utilization of these drugs for treating cystic fibrosis. CFTR modulators specifically target the production and function of the mutated CFTR protein, which regulates the movement of water and chloride in and out of cells lining the lungs and other organs. These drugs are regarded as potent therapeutics for managing the disease, with three main types: potentiators, correctors, and amplifiers.

In terms of the route of administration, the oral segment captured the majority of market share in 2018, primarily due to the growing availability of cystic fibrosis therapeutics in oral formulations. Presently, there are three CFTR modulator drugs approved by the U.S. FDA, all of which are oral tablets: ivacaftor (Kalydeco), Orkambi, and Symdeko. With the current trends in the cystic fibrosis therapeutics market, the oral route of administration is projected to experience the fastest growth rate during the forecast period.

𝐊𝐞𝐲 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐂𝐲𝐬𝐭𝐢𝐜 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭:

By drug class, the CFTR segment accounted for the highest market share of 65% in 2018 and is anticipated to grow at the fastest rate during the forecast period.
By region, Europe was the major shareholder and accounted for the highest share of 33% in 2018.
By route of administration, oral segment is expected to grow at a CAGR of 9.9% during the forecast period.
North America is anticipated to grow at the fastest CAGR of 9.8% during the forecast period.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲: https://www.alliedmarketresearch.com/purchase-enquiry/5499

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:
Genentech, Inc.
Novartis AG
Gilead Sciences, Inc.
Vertex Pharmaceuticals Incorporated
AbbVie Inc.
GlaxoSmithKline Plc.
Johnson & Johnson
Allergan plc
Pharmaxis Ltd.
Mylan N.V.

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞 https://www.alliedmarketresearch.com/cystic-fibrosis-therapeutics-market

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int'l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com
Allied Market Research Blog: https://blog.alliedmarketresearch.com
Follow Us on | Facebook | LinkedIn | YouTube |

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry

This release was published on openPR.